{
    "address": "Retzius Vag 8",
    "city": "Solna",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W989B0106",
    "description": "Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm and currently employs 51 full-time employees. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.",
    "employeeTotal": "51.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2016-02-03",
    "isin": "SE0007789409",
    "logo": "https://finnhub.io/api/logo?symbol=XBRANE.ST",
    "marketCapitalization": 3525.619,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Xbrane Biopharma AB",
    "phone": "46707187062.0",
    "sedol": "BYN69C7",
    "shareOutstanding": 22.200415,
    "state": "STOCKHOLM",
    "ticker": "XBRANE.ST",
    "weburl": "http://xbrane.com/"
}